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Summary
Tumor growth and metastasis require concomitant growth of new blood vessels, which are stimulated by angiogenic
factors, including vascular endothelial growth factor (VEGF), secreted by most tumors. Whereas the angiogenic property
and molecular mechanisms of VEGF have been well studied, the biological function of its related homolog, placenta growth
factor (PlGF), is poorly understood. Here we demonstrate that PlGF-1, an alternatively spliced isoform of the PlGF gene,
antagonizes VEGF-induced angiogenesis when both factors are coexpressed in murine fibrosarcoma cells. Overexpression
of PlGF-1 in VEGF-producing tumor cells results in the formation of PlGF-1/VEGF heterodimers and depletion of the majority
of mouse VEGF homodimers. The heterodimeric form of PlGF-1/VEGF lacks the ability to induce angiogenesis in vitro and
in vivo. Similarly, PlGF-1/VEGF fails to activate the VEGFR-2-mediated signaling pathways. Further, PlGF-1 inhibits the
growth of a murine fibrosarcoma by approximately 90% when PlGF-1-expressing tumor cells are implanted in syngeneic
mice. In contrast, overexpression of human VEGF in murine tumor cells causes accelerated and exponential growth of
primary fibrosarcomas and early hepatic metastases. Our data demonstrate that PlGF-1, a member of the VEGF family,
acts as a natural antagonist of VEGF when both factors are synthesized in the same population of cells. The underlying
mechanism is due to the formation of functionally inactive heterodimers.
Introduction angiogenesis, VEGF is an essential factor that contributes to
the development of the vascular system by stimulating vasculo-
genesis and angiogenesis during embryonic development (Car-Tumor growth and metastasis are dependent on the degree of
meliet et al., 1996; Ferrara et al., 1996).neovascularization in the tumor bed (Carmeliet and Jain, 2000;
The VEGF family is comprised of five structurally relatedFolkman, 1995; Hanahan and Folkman, 1996). Vascular endo-
members, including VEGF-A, placenta growth factor (PlGF),thelial growth factor/vascular permeability factor (VEGF/VPF) is
VEGF-B, VEGF-C, and VEGF-D (Eriksson and Alitalo, 1999).a key angiogenic factor, frequently utilized by tumors and other
The biological functions of the VEGF family are mediated bytissues to switch on blood vessel growth (Benjamin and Keshet,
1997; Dvorak, 2000; Ferrara and Alitalo, 1999; Senger et al., activation of three structurally homologous tyrosine kinase re-
ceptors, VEGFR-1, VEGFR-2, and VEGFR-3 (Cao et al., 1998).1983; Yancopoulos et al., 2000). In addition to pathological
S I G N I F I C A N C E
Although VEGF is one of the most frequently expressed angiogenic factors found in tumors, PlGF-1, as an alternatively spliced isoform
of the PlGF gene and structurally related to VEGF, does not seem to induce angiogenesis. In contrast, PlGF-2, a heparin binding
isoform of PlGF, is able to induce angiogenesis. Some previous studies suggested that PlGF-1 might potentiate VEGF-induced
angiogenesis by competing with VEGF for the decoy VEGFR-1 receptor, thus making more VEGF molecules available for interaction
with VEGFR-2, which transduces the angiogenic signals. Our present work provides evidence that PlGF-1 acts as a natural antagonist
of VEGF when both factors are coexpressed in the same population of cells. The underlying antagonistic mechanism is due to the
formation of functionally inactive PlGF-1/VEGF heterodimers. Our results demonstrate that other members of the VEGF family can
antagonize VEGF-induced angiogenesis. Taken together with work by others, we propose a novel mechanistic principle according
to which PlGF-1 plays dual roles in regulation of VEGF-induced angiogenesis in both positive and negative manners, depending
upon the temporal and spatial relations of expression of these two factors. Our work also has conceptual implications for gene
therapy in cancer treatment by targeting PlGF-1 to tumors.
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VEGF and PlGF-2 also bind to a nontyrosine kinase receptor,
neuropilin-1 (Migdal et al., 1998; Soker et al., 1998). However,
the biological signals mediated by neuropilin-1 in endothelial
cells are not known. According to their receptor binding patterns
and angiogenic features, the members of the VEGF family can
be further divided into three subgroups: (1) VEGF, which binds
to VEGFR-1 and VEGFR-2, and induces vasculogenesis, angio-
genesis, and vascular permeability; (2) PlGF and VEGF-B, which
bind only to VEGFR-1, with unknown physiological and patho-
logical functions; and (3) VEGF-C and VEGF-D, which interact
with both VEGFR-2 and VEGFR-3, and induce both blood angio-
genesis and lymphangiogenesis (Cao et al., 1998; Makinen et
al., 2001; Marconcini et al., 1999; Skobe et al., 2001; Stacker et
al., 2001). Accumulating evidence has suggested that VEGFR-2,
in response to VEGF, mediates angiogenic signals for blood
vessel growth, and VEGFR-3 transduces signals for lymphatic
vessel growth (Dvorak, 2000; Ferrara and Alitalo, 1999). The
function of VEGFR-1 is poorly understood. While some studies
suggest a direct role in transducing angiogenic signals, others
report that VEGFR-1 may act as a decoy receptor for VEGF/
VEGFR-2 signaling (Hiratsuka et al., 2001; Landgren et al., 1998;
Zeng et al., 2001). Similar to VEGF, PlGF can be generated as
at least three alternatively spliced isoforms of the same gene:
PlGF-1, PlGF-2, and PlGF-3 (Cao et al., 1997; Maglione et al.,
1991; Maglione et al., 1993).
Similar to the platelet-derived growth factor (PDGF) family,
all members in the VEGF family naturally exist as dimeric pro-
teins in order to interact with their specific receptors. In addition
to homodimers, PlGF and VEGF-B can form heterodimers with
VEGF when these factors are produced in the same cell (Cao
et al., 1996a; DiSalvo et al., 1995; Olofsson et al., 1996). We
have previously reported that PlGF-1 preferentially forms
heterodimers with VEGF intracellularly (Cao et al., 1996a,
1996b). PlGF-1/VEGF heterodimers are naturally present in tis-
sues when both factors are synthesized in the same population
of cells (Cao et al., 1996a, 1996b; DiSalvo et al., 1995). Our
previous results and those of others showed that PlGF-1/VEGF
heterodimers, unlike VEGF homodimers, exhibit only a weak stimu-
lation of endothelial cells, suggesting that PlGF-1 might act as a
negative regulator for VEGF (Cao et al., 1996a; Kurz et al., 1998).
To further test this hypothesis we have studied the role of PlGF-1
in primary tumor growth and metastasis of a murine fibrosarcoma.
Results
Generation of PlGF/VEGF heterodimers
To generate heterodimeric forms of PlGF/VEGF, we expressed Figure 1. Corneal angiogenesis
recombinant human PlGF-1 and VEGF165 monomers with differ- A: VEGF, PlGF-1, and PlGF-1/VEGF were purified to homogeneity and ana-
ent molecular weights. Using protocols described in the Experi- lyzed under reducing (lanes 2, 4, and 6) and nonreducing (lanes 1, 3, and
mental Procedures, recombinant PlGF-1 and VEGF165 mono- 5) conditions.
B–F: 160 ng of VEGF (C), PlGF-1 (D), PlGF-1/VEGF (E), or PlGF-1 (160 ng) plusmers purified from bacterial lysates could be readily dimerized
VEGF (160 ng) (F) were implanted into corneas of C57BL/6. Polymers withoutinto a mixture of homodimers and heterodimers of PlGF-1/
growth factors were used as negative controls (B). Arrows point to thePlGF-1, VEGF165 /VEGF165, and PlGF-1/ VEGF165 after removal implanted pellets.
of the reducing reagent, DTT. Each of these dimers was highly G: Areas of neovascularization were measured according to protocols de-
scribed in the Experimental procedures.purified to homogeneity by affinity chromatography (Figure 1A).
These dimeric proteins were converted to monomers under
reducing conditions as analyzed by electrophoresis (Figure 1A).
et al., 1998). As expected, VEGF homodimers induced a robust
PlGF-1/VEGF heterodimers lack angiogenic activity corneal angiogenic response with a high number of microves-
To test their in vivo angiogenic features, we analyzed all three sels forming a primitive vascular network at the leading edge
(Figure 1C). In contrast, the same amount of PlGF-1 homodimersdimeric factors in the mouse corneal angiogenesis model (Cao
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or PlGF-1/VEGF heterodimers failed to stimulate corneal angio-
genesis (Figures 1D and 1E). PlGF-1 did not seem to interfere
with VEGF-induced neovascularization when both PlGF and
VEGF homodimers were coimplanted in mouse corneas (Figure
1F). Quantification of corneal neovascularization showed that
PlGF-1 and PlGF-1/VEGF lacked detectable angiogenic re-
sponses in this in vivo assay (Figure 1G).
Formation of PlGF-1/VEGF heterodimers in tumor cells
Because PlGF-1 forms functionally defective heterodimers with
VEGF in vitro, we hypothesized that overexpression of PlGF-1
could lead VEGF molecules to form PlGF-1/VEGF heterodimers
in tumor cells and thus antagonize the angiogenic activity of
VEGF produced by tumors. To test this hypothesis, we ex-
pressed hPlGF-1 to a high level using a retroviral vector in a well-
characterized murine fibrosarcoma with a VEGF-dependent in
vivo growth (Kuo et al., 2001). The presence of hPlGF-1 and
hVEGF cDNAs was confirmed by Southern blot analysis. Over-
expression of hVEGF in murine fibrosarcoma cells resulted in the
formation of hVEGF/hVEGF homodimers and hVEGF/mVEGF
heterodimers that were coprecipitated by an antibody specific
to hVEGF (Figure 2B, lane 2). The different forms of VEGF dimers
were converted to monomers under reducing conditions (Figure
2B, lane 3). In addition to the mVEGF164 isoform, mVEGF120 also
participated in the formation of heterodimers with hVEGF165.
Similarly, high levels of hPlGF-1 expression resulted in the for-
mation of hPlGF-1/hPlGF-1 homodimers and hPlGF-1/mVEGF
heterodimers as detected in complexes precipitated by a spe-
cific anti-hPlGF-1 antibody (Figure 2A). These dimers were re-
duced to monomers in the presence of a reducing agent (Figure
2A, lane 3).
To quantify the amounts of various dimeric molecules se-
creted by tumor cells, we performed a sensitive sandwich ELISA
assay using specific antibodies against each factor (Table 1),
either two antibodies against the same factor but raised in differ-
ent species (homodimers), or two antibodies against different Figure 2. Dimer formation, chemotactic activity, and receptor phosphoryla-
factors (heterodimers). As expected, a high level of mVEGF tions
homodimers (2430 pg/ml) was detected in conditioned medium Radiolabeled complexes of hPlGF-1 homodimers and hPlGF-1/mVEGF het-
from wt T241 tumor cells. The majority of mPlGF produced erodimers produced by tumor cells were immunoprecipitated by an anti-
hPlGF-1 antibody (A). Immunocomplexes of hVEGF homodimers andby wt T241 was involved in heterodimerization with mVEGF,
hVEGF/mVEGF heterodimers were precipitated with an anti-hVEGF anti-suggesting that mPlGF preferentially formed heterodimers with
body (B). The dimeric (lane 2) and monomeric (lane 3) forms of growthmVEGF, rather than mPlGF/mPlGF homodimers. Only low levels factors were analyzed under nonreducing and reducing conditions. Condi-
of mVEGF homodimers (770 pg/ml) were found in the condi- tioned medium (CM) from wt T241 cells was used as negative control (lane
1). Pure growth factors (C and E) or conditioned media (D and E) derivedtioned media of hPlGF-T241-1 and hPlGF-T241-2 cells grown at
from wt T241, hVEGF-T241, and hPlGF-1-T241 cells were added to the lowerthe same conditions. In contrast, virtually all mVEGF molecules
chamber, and VEGFR-2/PAE (C and D) or VEGFR-1/PAE (E and F) cells werewere present as hPlGF-1/mVEGF heterodimers in PlGF-1-over-
seeded in the upper chamber. Migrating cells were counted per optic field
expressing hPlGF-T241-1 (7,500 pg/ml) and hPlGF-T241-2 tu- (32). Data represent means (SEM) of a triplicate of each sample. G: In
mor cells (73,000 pg/ml) (Table 1). Although different levels of response to growth factors, cell lysates from VEGFR-1/PAE and VEGFR-2/
PAE were blotted onto a nitrocellulose membrane and detected with anhPlGF were produced in hPlGF-T241-1 and hPlGF-T241-2 tu-
anti-phospho-tyrosine antibody.mor cells, both these high levels efficiently depleted mVEGF
homodimers.
Lack of stimulatory activity on endothelial cells
of hVEGF enhanced the chemotactic activity produced by T241by PlGF-1-overexpressing cells in vitro
cells. In contrast, both PlGF-1 homodimers and PlGF-1/VEGFTo study the chemotactic activity, we tested the effect of condi-
heterodimers lacked such a chemotactic effect on these endo-tioned media derived from various transduced and nontrans-
thelial cells, and expression of hPlGF-1 completely abolishedduced cells in a modified Boyden chemotaxis assay. As ex-
the chemotactic effect produced by T241 cells (Figure 2D). Nonepected, VEGF elicited a strong chemotactic response on
of these factors or conditioned media induced VEGFR-1/PAEVEGFR-2-expressing PAE cells (Figure 2C). Similarly, condi-
cell motility (Figures 2E and 2F). Similar results were obtainedtioned medium from wt T241 cells significantly stimulated
VEGFR-2/PAE cell migration (Figure 2D). High expression levels with primary HUVE cells (data not shown).
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mVEGF. This effect was completely abrogated after expressionTable 1. Quantification of dimeric factors secreted by tumor cells
of hPlGF-1, indicating that a majority of the mVEGF moleculesGrowth factors wt T241 hVEGF-T241 hPIGF-T241-1 hPIGF-T241-2
participated in formation of heterodimers with hPlGF-1 (Figure
(pg/ml) (pg/ml) (pg/ml) (pg/ml) 3K). In contrast, overexpression of hVEGF in T241 cells led to
mVEGF/mVEGF 2430 2000 770 770
remarkable cell shape changes and actin reorganization (FiguremPIGF-1/mPIGF-1 630 80 700 400
3G). Again, conditioned media from all cell lines failed to inducemPIGF-1/mVEGF 2400 140 370 230
hPIGF-1/hPIGF-1 ND ND 7500 73000 a similar change in endothelial morphology of VEGFR-1/PAE
hPIGF-1/mVEGF ND ND 6500 23000 cells (Figures 3D, 3H, and 3L).
hVEGF/hVEGF ND 567000 ND ND
ND  Not detectable Lack of activation of the VEGFR-2-mediated
signaling pathway
Consistent with previous findings (Ferrara and Alitalo, 1999),
VEGFR-2 became heavily phosphorylated upon VEGF stimula-
tion (Figure 2G). In contrast, PlGF-1 and PlGF-1/VEGF wereAddition of hVEGF homodimers at the concentration of 50
unable to induce phosphorylation of VEGFR-2 under the sameng/ml to VEGFR-2/PAE cells induced a spindle-like cell shape
conditions. However, they efficiently activated phosphorylationwith reorganization of actin fibers (Figure 3E), a feature that
of VEGFR-1 (Figure 2G). To quantify the levels of intracellularboth PlGF-1 homodimers and PlGF-1/VEGF heterodimers lack
inositol phosphates (InsPs), one of the mediators for VEGFR-2(Figures 3I and 3M). Furthermore, VEGFR-1-expressing PAE
signal transduction, a sensitive radiolabeling method was used.cells did not respond to any of these three factor treatments
As expected, VEGF produced increases of InsP1, InsP2, and(Figures 3F, 3J, and 3M). Incubation with conditioned medium
InsP3 production in VEGFR-2/PAE cells (Table 2). In contrast,from wt T241 cells resulted in an elongated spindle-like cell
neither PlGF-1, PlGF-1/VEGF, nor conditioned media of PlGF-1shape in VEGFR-2/PAE cells, similar to that induced by hVEGF
(Figure 3C), confirming that T241 cells secrete high levels of overexpressing tumor cell lines stimulated significantly in-
Figure 3. Endothelial cell shape changes and
actin reorganization
Pure hVEGF (E and F), hPlGF-1 (I and J), PlGF-1/
VEGF (M and N) or CM derived from wt T241
(C and D), hVEGF-T241 (G and H), and hPlGF-1-
T421-1 (K and L) cells were added to approxi-
mately 50%–60% confluent VEGFR-2/PAE cells (A,
C, E, G, I, K, and M) or VEGFR-1/PAE (B, D, F, H,
J, L, and N) for 16 hr. In response to VEGF (E),
wt T241 CM (C), and hVEGF-T241 CM (G), PAE/
VEGFR-2 cells underwent dramatic spindle-like
shape changes. Incubation of VEGFR-2/PAE cells
without growth factors served as a negative con-
trol (A). VEGFR-1/PAE did not show any morpho-
logical changes in response to these stimuli (B,
D, F, H, J, L, and N). O: Quantification of spindle-
like cells.
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of tumor growth was scored in hPlGF-1-expressing tumors asTable 2. Analysis of inositol phosphate production
compared with the wt T241 tumors (Figures 4B and 4D). Simi-InsP1 InsP2 InsP3
larly, highly significant reductions of primary tumor volumesCell line Treatment (cpm) (cpm) (cpm)
were found in both PlGF-1-expressing tumor clones (Figure 4C).
VEGFR-2/PAE No factor 1421 518 84
Immunohistochemical studies showed that hPlGF-1-expressingVEGF 7868 1414 336
tumors had significantly reduced neovascularization as com-PIGF-1 1913 331 23
PIGF-1/VEGF 2019 692 142 pared with wt T241 tumors (Figures 5A, 5C, and 5D). In contrast,
hVEGF-T241 4724 1155 402 hVEGF-expressing tumors were highly vascularized with an av-
hPIGF-T241-1 1568 316 69
erage of more than 300 microvessels per optical field (10)hPIGF-T241-2 1517 335 74
(Figures 5B and 5D). In addition to high vessel counts, some ofVEGFR-1/PAE No factor 261 179 77
VEGF 371 173 56 the microvessels were dilated with a thin endothelial layer (Figure
PIGF-1 398 147 43 5B). The invasive growth feature of hVEGF-expressing tumors
PIGF-1/VEGF 355 199 27 led to early metastasis of tumor cells into other organs suchhVEGF-T241 509 181 18
as spine and liver. Biopsy examination revealed that 100% ofhPIGF-T241-1 276 183 20
hPIGF-T241-2 409 203 10 hVEGF-T241 tumor bearing mice had hepatic metastases (Fig-
ure 5E). Both liver volume and weight of hVEGF-T241 tumor
bearing mice were significantly larger than those of control ani-
mals (Figures 5E and 5F). Overproduction of VEGF by tumor
cells not only resulted in hemorrhagic lesions in hepatic metasta-creased levels of InsP1, InsP2, and InsP3 in these cells. None
ses (Figure 5H, arrowheads), but also caused destruction ofof these growth factors or conditioned media stimulated InsP
regular hepatocyte sinusoidal organization as compared to liversynthesis in VEGFR-1/PAE cells.
structures of wt T241- or hPlGF-1-T241-tumor bearing mice
(Figures 5G and 5I).Suppression of tumor growth
Overexpression of hPlGF-1 in T241 cells did not alter the growth
Discussionrates of two independent tumor clones in culture (Figure 4A).
The wt T241 tumor cells grew rapidly in vivo, and visible tumors
The members of the VEGF family are considered to be keywere readily detectable 6 days after implantation (Figure 4B).
angiogenic mediators contributing to both physiological andExpression of hVEGF in these cells significantly accelerated
pathological angiogenesis (Schratzberger et al., 2000). Ourtumor growth (Figure 4B). Tumors expressing hVEGF grew inva-
present study demonstrates that PlGF-1, a member of this fam-sively into surrounding tissues and resulted in early visible me-
ily, could act as an antagonist of its prominent homolog, VEGF.tastases in other organs such as spine and liver. In contrast,
The antagonistic effect of PlGF-1 in opposing VEGF requiresexpression of hPlGF-1 remarkably delayed tumor growth, and
coexpression of both factors in the same cells. Our results showvisible tumors were only detectable by day 12 after implantation
that the molecular mechanism of the anti-VEGF effect by PlGF-1(Figure 4B). These tumors remained at a similar small average
is due to the formation of functionally inactive PlGF-1/VEGFsize of about 70 mm3 by day 16 after implantation (Figure 4B).
At day 16 after tumor implantation, approximately 90% inhibition heterodimers. These heterodimers fail to activate the key angio-
Figure 4. Suppression of tumor growth
A: Tumor cell growth rates. Monolayers of wt
T241, hPlGF-T241-1, hPlGF-T241-2, and VEGF-T241
tumor cells growing in 24-well plates at the den-
sity of 5,000 cells/well were incubated for indi-
cated time points and cell numbers were
counted. B: Approximately 1  106 cells of wt
T241, hVEGF-T241, hPlGF-T241-1, or hPlGF-T241-2
cells were subcutaneously injected into 6-week-
old C57BL/6 male mice. Tumor sizes were mea-
sured every other day. At day 14 after tumor
implantation, typical tumor appearance was
photographed (D) and tumor burdens were
weighed after necropsy at day 18 (C). Yellow
arrows indicate the implanted tumors (D).
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Figure 5. Immunohistochemical analysis of primary tumors and hepatic metastases
At day 18 after tumor implantation, primary tumors (A–C) were resected and stained with an anti-CD31 antibody. Arrows point to tumor microvessels (A–C).
Microvessel density was counted under a light microscope in at least 5 random fields (G). ***, P  0.001. Livers of each group were optically analyzed for
their appearance (E). Large numbers of hepatic metastases were visible on the surface of all livers of hVEGF-T241-bearing mice (E). Liver burdens were
weighed and mean values of each group (6 mice) were presented as SEM (F). ***, P  0.001. Histological analysis of hepatic metastases was performed
after staining with hemotoxylin-eosin at 10 magnification (G–I). Hepatic metastases in hVEGF-T241-implanted mice (H) are marked with a dashed line.
Arrowheads (H) point to hemorrhagic microvessels in metastases. Met, metastasis; L, liver.
genic receptor of VEGF, VEGFR-2, and VEGFR-2-mediated sig- PlGF-1 (Kendall and Thomas, 1993; Park et al., 1994). Deletion
of VEGFR-1 results in early embryonic lethality due to disorgani-naling pathways. We further provide evidence showing that
gene delivery of PlGF-1 to VEGF-producing tumors suppresses zation and inappropriate remodeling of the vascular tube struc-
tures (Fong et al., 1995). However, the defective phenotype oftumor growth and may have conceptual implications in the treat-
ment of cancer and metastasis. VEGFR-1 null mice shows that endothelial cell number is not
affected, suggesting that VEGFR-1-mediated signals are notPlGF-1 was discovered more than 10 years ago as the sec-
ond member of the VEGF family based on its structural homol- critical for endothelial cell proliferation and migration. Interest-
ingly, removal of the tyrosine kinase domain of VEGFR-1 didogy with VEGF (Maglione et al., 1991, 1993; Persico et al.,
1999; Schratzberger et al., 2000). Since the identification of this not alter developmental angiogenesis (Hiratsuka et al., 1998).
Therefore, VEGFR-1 may function as a decoy receptor by lim-molecule, it has been speculated that PlGF-1 might act as an
angiogenic factor (Maglione et al., 1991). Whereas a couple of iting the bioavailability of VEGF to bind to VEGFR-2. In support
of this hypothesis, some reports show that administration ofstudies suggest that it stimulates endothelial cell proliferation
or migration, most other work demonstrates that PlGF-1 alone PlGF-1 protein in cell culture and animal models leads to potenti-
ation of VEGF-induced angiogenesis in vitro and in vivo, possiblyis insufficient to induce neovascularization (Cao et al., 1996a,
1996b; Carmeliet and Jain, 2000; Clauss et al., 1996; Park et by competing with VEGF for the binding site of VEGFR-1 (Car-
meliet et al., 2001; Park et al., 1994). However, the VEGF recep-al., 1994). VEGFR-1 is the only known signaling receptor for
104 CANCER CELL : FEBRUARY 2002
A R T I C L E
tor-mediated signals might be more complex because VEGFR-1
and VEGFR-2 form both homodimers and heterodimers (Huang
et al., 2001). It is not known if VEGFR-1/VEGFR-2 heterodimers
mediate angiogenic responses, and if so, which ligands trigger
angiogenesis.
Within the PlGF family, at least three PlGF isoforms (i.e.,
PlGF-1, PlGF-2, and PlGF-3) have been identified, all generated
by alternative splicing of the same gene (Cao et al., 1997; Magli-
one et al., 1991, 1993). It appears that PlGF-2, a heparin binding
isoform, possesses additional biochemical and biological prop-
erties, such as binding to the neuropilin-1 receptor (Migdal et
al., 1998). PlGF-1 is less active than PlGF-2 in stimulation of
endothelial cell growth and angiogenesis (Sawano et al., 1996;
Ziche et al., 1997). Thus, it is possible that additional biological
activities of PlGF-2, but not PlGF-1, including stimulation of
angiogenesis, could be mediated by the neuropilin-1 receptor.
The fact that activation of neuropilin-1 potentiates angiogenic
responses mediated by VEGF tyrosine kinase receptors sup-
ports this finding (Soker et al., 1998). Thus, it is not surprising Figure 6. Schematic representation of dual roles of PlGF-1 in regulation of
that transfection of the PlGF-2 gene in tumor cells does not VEGF-induced angiogenesis
significantly alter tumor growth (Hiratsuka et al., 2001). It is When PlGF-1 and VEGF are produced in different cells, PlGF-1 enhances
the VEGF-stimulated angiogenesis. In contrast, PlGF-1 antagonizes the an-possible that PlGF-1, but not PlGF-2, is a natural antagonist
giogenic activity of VEGF when both factors are coexpressed in the samefor VEGF when produced as a heterodimer with VEGF. Thus,
population of cells.
regulation of alternative splicing of PlGF isoforms in various
tissues could possibly act as an operator in the switch of VEGF-
induced angiogenesis.
A recent study suggests that PlGF-1 produced by tumor PlGF-1 could potentiate, rather than inhibit, VEGF-induced an-
and host cells may positively contribute to angiogenesis and giogenesis in the placenta, as shown in Figure 6.
tumor growth (Carmeliet et al., 2001). However, these data do Our present findings are similar to the functional properties
not seem to conflict with our current observation. In that report, of the angiopoietin family, in which Ang-2 acts as a natural
the level of PlGF-1 expression in the tumors was several times antagonist of Ang-1 (Maisonpierre et al., 1997). However, the
lower than that of VEGF. It is not known whether all VEGF antagonistic mechanism of Ang-2 is different from that of PlGF-1
molecules expressed in that tumor participate in heterodimeriza- in such a way that Ang-2 competes with Ang-1 for binding to
tion with PlGF-1. In addition, PlGF-1 expressed in host cells the Tie-2 receptor, whereas PlGF-1 forms functionally inactive
cannot form heterodimers with VEGF produced by the tumor, heterodimers with VEGF. Our findings provide an example of a
and may thus instead potentiate VEGF-induced tumor angio- growth factor acting as an antagonist of its structurally related
genesis. Our present work demonstrates that high levels of analog. Our present work not only increases the understanding
PlGF-1 expression in VEGF-producing tumors force VEGF to of the complex functions of the VEGF family, but also provides
form functionally inactive heterodimers and thus neutralize a novel conceptual implication of PlGF-1 as an antagonist in
VEGF activity. We should emphasize that PlGF-1 antagonizes the treatment of VEGF-dependent diseases.
VEGF-induced angiogenesis only if both factors are simultane-
Experimental proceduresously synthesized in the same population of cells. Therefore,
PlGF-1, as shown in Figure 6, may play dual roles in regulation
Animalsof VEGF-induced angiogenesis and tumor growth. When these
Male 6- to 7-week-old C57BL/6 mice were acclimated and caged in groupstwo factors are produced in different cell populations, PlGF-1
of six or less. Animals were anesthetized by an injection of a mixture of
competes with VEGF for VEGFR-1, increasing the bioavailability dormicum and hypnorm (1:1) before all procedures and killed with a lethal
of VEGF, thus allowing excess of VEGF molecules to bind dose of CO2. All animal studies were reviewed and approved by the animal
care and use committee of the Stockholm Animal Board.VEGFR-2, which triggers angiogenic responses. On the other
hand, PlGF-1 acts as an antagonist for VEGF by formation of
Generation and purification PlGF-1/VEGF165 heterodimersbiologically inactive PlGF-1/VEGF heterodimers and depletion
Recombinant human PlGF-1 and VEGF165 monomers were expressed in E.of VEGF homodimers when both factors are coexpressed in the
Coli as previously described (Maisonpierre et al., 1997). An equimolar of
same cell populations. mixture of PlGF-1 and VEGF165 at a total protein concentration of 0.5 mg/
Unlike VEGF, the expression pattern of PlGF-1 under physio- ml was incubated in 20 mM Tris-HCl (pH 8.0), 6 M guanidine-HCl, and 10
mM DTT. After overnight incubation at 4C, the protein solution was dialyzedlogical conditions is limited to only a few tissues in adult mam-
overnight at 4C against 10 volumes of 2 M urea, 2 mM GSH (glutathione-mals. Placenta is perhaps the only tissue that expresses PlGF-1
SH), and 0.5 mM GSSG (glutathione-S-S-glutathione) in 20 mM Tris-HClat extremely high levels. VEGF has been detected at high levels
(pH 8.0). Using this refolding protocol, a mixture of homodimeric PlGF-1in the placenta as well. However, a recent study indicates that
and VEGF165 as well as heterodimeric PlGF-1/VEGF was generated.
mRNAs for VEGF and PlGF-1 are not colocalized, and it is thus The homodimeric and the heterodimeric proteins were separated from
unlikely that there is any significant production of PlGF-1/VEGF one another by affinity chromatography using a goat polyclonal anti-VEGF
antibody affinity column and a polyclonal goat anti-PlGF antibody affinityheterodimers in the placenta (Clark et al., 1998). Accordingly,
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column. The protein solution was applied at a flow rate of 2 ml/min initially were washed with ice cold PBS/0.1 mM NaV3O4 and lysed on ice in 200 l
lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5% Na-on the anti-VEGF antibody-affinity column equilibrated with PBS. The column
was then washed at the same flow rate with PBS until the absorbance deoxycholate, 0.5% Triton X-100, 1 mM PMSF, 1 ng/ml aprotinin/leupeptin,
0.1 mM NaV3O4). The proteins were blotted onto nitrocellulose membranesreading at 280 nm reached baseline level. VEGF homodimers and PlGF-1/
VEGF heterodimers, but not PlGF homodimers, were retained by the column and blocked overnight in 5% BSA in TBS-T, and probed with a primary
monoclonal mouse antibody against pTyr (PY20, Pharmingen, San Diego,and eluted with 0.1 M sodium citrate, 0.3 M NaCl (elution buffer). The VEGF
homodimers and PlGF-1/VEGF heterodimers eluted from the anti-VEGF col- CA), a secondary HRP-conjugated antibody against mIgG, and detected
using the ECL system.umn were dialyzed against 20 volumes of PBS at 4C for 4 hr and applied
to the anti-PlGF-affinity column under the same conditions. The heterodimer
was then eluted by the same elution buffer. The purified PlGF-1, VEGF, and HPLC analysis of inositol phosphate production
PlGF-1/VEGF proteins were finally dialyzed against PBS and analyzed by For inositol phosphate measurements, cells were grown to confluency in
SDS-PAGE, followed by measurement of protein concentrations. culture dishes (6 cm2) and incubated for 24 hr with 10 Ci/ml myo-[2-
3H]inositol in Krebs-Ringer bicarbonate medium containing 0.5 mM adeno-
sine, 10 mM inosine, and 5 mM -hydroxybutyrate. After incubation, cellsRetroviral vector design and tumor cell transduction
Complementary cDNAs coding for human PlGF-1129 and VEGF165 were cloned were washed twice with KRB medium and cellular activity was stopped by
adding 250 l ice-cold 400 mM PCA. After centrifugation for 2 min at 1200 g,into the Murine Stem Cell Virus (MSCV) vector (kindly provided by Dr. R.
Hawley at the Holland Laboratory, Rockville, MD) containing EGFP. Retroviral 250 l of the supernatant from each tube was neutralized by addition of 47
supernatants were generated by transfecting retroviral constructs into l ice-cold 2.5 M KOH  0.5 M HEPES. Inositol phosphates were separated
293T cells along with expression plasmids encoding ecotropic gag/pol and on a HPLC system using an anion-exchange column (mono Q HR 5/5,
the Vesicular Stomatitis Virus-Glycoprotein (VSV-G) envelope using a classi- Pharmacia Biotech, Sweden) equilibrated with 10 mM NH4COOH. The inosi-
cal CaPO4 transfection method (Pawliuk et al., 1994). Murine T241 fibrosar- tol phosphates were eluted by a 0%–100% gradient of 1.7 M NH4COOH
coma cells grown in log phase were exposed to filtered viral supernatants in (pH 3.7).
the presence of 8g/ml of protamine sulfate on RetronectinTM (Biowhittaker,
East Rutherford, NJ) coated culture dishes for 6 hr on two consecutive days. Metabolic labeling
EGFP positive cells were sorted using a FACStar (Becton Dickinson, San Cells growing to subconfluency in 25 cm2 flasks were incubated with methio-
Jose, CA) equipped with a 5 W argon and 30 mW neon laser. PCR and nine- and serum-free DMEM for 45 min, followed by pulse-labeling with 50
Southern blot analyses were performed using standard methods (Pawliuk Ci/ml of 35S-methionine (Amersham-Pharmacia Biotech, Uppsala, Sweden)
et al., 1994). for 16 hr. The labeled medium was removed and subjected to immunoprecip-
itation with goat anti-human PlGF-1, goat anti-mouse VEGF, and mouse
Tumor cell proliferation assay anti-human VEGF antibodies (R&D Systems Inc., Minneapolis, MN) for 1 hr
wt T241, hVEGF-T241, and hPlGF-1-T241 cells were seeded at a density at 4C. The immunocomplexes were precipitated with Protein A-Sepharose
of 1  104 cells/well in 24-well plates in DME medium supplemented with or Protein G-Sepharose for 1 hr at 4C. The immunoprecipitated materials
10% FCS and incubated at 37C. Cells were trypsinized, resuspended in were released by a SDS buffer and separated by a Nu-PAGE gel under
Isoton II solution (Beckman Coulter, Sweden), and counted in a Coulter reducing or nonreducing conditions.
Counter at various time points. All experiments were performed in triplicates.
ELISA assay
Cell shape assay and actin staining The sandwich ELISAs were performed using the Quantikine ELISA (R&D
VEGFR-1/PAE and VEGFR-2/PAE cells were grown on coverslips in 12-well Systems) according to the manufacturer’s instructions. Briefly, the standard
plates to about 40%–60% confluency in Ham’s F12 medium supplemented mouse (m) VEGF and samples were added onto a 96-well microplate pre-
with 10% FCS as previously described (Cao et al., 1998). The medium was coated with an affinity purified polyclonal antibody specific for mVEGF, which
removed and replaced with fresh Ham’s F12 medium containing 2% FCS were detected by an enzyme-linked polyclonal antibody specific for mVEGF.
with or without 50 ng/ml of VEGF, PlGF-1, PlGF-1/VEGF, or 25% (v/v) of Similarly, homodimers of mPlGF, hVEGF, and hPlGF were measured using
conditioned media. After 16 hr, cells were fixed with 3% paraformaldehyde the Quantikine M mPlGF ELISA kit, Quantikine hVEGF ELISA kit, and Quan-
(PFA) in PBS (pH 7.5) for 30 min, rinsed three times with PBS, and permeabil- tikine hPlGF ELISA kit, respectively. These three kits contain specific mono-
ized with 0.5% Triton X-100 in PBS for 15 min. The cells were then washed clonal antibodies as captures.
three times with PBS and stained for 30 min with 1 g/ml of TRITC-phalloidin The heterodimers were measured by crossmatching capture and detec-
(Sigma) in PBS. After washing three times with PBS, the coverslips were tion antibodies using the same ELISA kits mentioned above. For mVEGF/
mounted in a mixture of glycerol and PBS (9:1). Cells were examined in a mPlGF heterodimers, samples were added onto microplates precoated with
combined light and fluorescence microscope, and spindle-like cells were anti-mVEGF. Enzyme-linked anti-mPlGF was then used to detect the
counted in 3–4 optical fields (20). Data represents mean % (SEM) mVEGF/mPlGF heterodimer. To calibrate the assay, recombinant mPlGF
standard was analyzed simultaneously on the PlGF plate. No crossreactivity
was observed from the homodimers. Likewise, mouse/human VEGF hetero-Chemotaxis assay
The motility response of VEGFR-expressing PAE cells to various growth dimer was measured using microplates precoated with anti-hVEGF and
anti-mVEGF conjugates. Recombinant mVEGF standards analyzed on thefactors and conditioned media was assayed by a modified Boyden chamber
technique as previously described using micropore nitrocellulose filters (8 mVEGF plates were used for calibration. Approximately 1%–2% of cross-
reactivity was observed from each homodimer, and the results were cor-m thick, 8 m pores) (Cao et al., 1998). Cells were trypsinized and resus-
pended at 0.8  106 cells/ml in serum-free medium containing 0.2% BSA. rected accordingly. mVEGF/hPlGF heterodimer was measured using mi-
croplates precoated with anti-mVEGF and the anti-hPlGF conjugate.The cells (40,000 cells per well) were applicated to the upper chamber in
medium with or without 50 ng/ml of VEGF, PlGF-1, PlGF-1/VEGF heterodim- Recombinant hPlGF standards analyzed on the hPlGF plates were used for
calibration. Approximately 3% of crossreactivity were observed from theers, or 25% (v/v) conditioned media from different retrovirally transduced
cells in the lower chamber. After 4 hr at 37C, the Boyden chamber was hPlGF homodimer, and the results were corrected accordingly.
disassembled and cells attached to the filter were fixed in methanol and
stained with Giemsa solution. All experiments were performed in triplicate. Mouse corneal micropocket assay
The cells that had migrated through the filter were counted and plotted as The mouse corneal assay was performed according to procedures previously
number of migrating cells per optic field (32). described (Cao et al., 1998, 1996b). Corneal micropockets were created
with a modified von Graefe cataract knife in both eyes of each male 5- to
6-week-old C57BL/6 mouse. A micropellet (0.35  0.35 mm) of sucroseDetection of phosphorylated VEGF receptors
VEGFR-1/PAE and VEGFR-2/PAE cells were grown to 70%–80% confluency aluminum sulfate (Bukh Meditec, Copenhagen, Denmark) coated with hydron
polymer type NCC (IFN Sciences, New Brunswick, NJ) containing 160 ngin 60 mm dishes, starved for 16 hr in serum-free F12/Ham, and stimulated
with 50 ng/ml VEGF, PlGF-1, or PlGF-1/VEGF for 8 min at 37C. The cells of PlGF-1, VEGF, or PlGF-1/VEGF was implanted into each corneal pocket.
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tor K1–5 generated by plasmin-mediated proteolysis. Proc. Natl. Acad. Sci.The pellet was positioned 1.0–1.2 mm from the corneal limbus. After implan-
USA 96, 5728–5733.tation, erythromycin/ophthalmic ointment was applied to each eye. Eyes
were examined by a slit-lamp biomicroscope on day 5 after pellet implanta- Carmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other dis-
tion. Vessel length and clock hours of circumferential neovascularization eases. Nature 407, 249–257.
were measured.
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein,
M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996).Tumor studies in mice
Abnormal blood vessel development and lethality in embryos lacking a singleWild-type, hPlGF-1-expressing (hPlGF-T241-1 and hPlGF-T241-2) and
VEGF allele. Nature 380, 435–439.hVEGF-expressing (hVEGF-T241) murine T241 fibrosarcoma cells were used
for tumor implantation studies in 6- to 7-week-old syngeneic C57BL/6 mice. Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol,
Approximately 1  106 tumor cells were implanted subcutaneously in each M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001). Synergism between
mouse. Six to seven mice were used in the treated and control groups. vascular endothelial growth factor and placental growth factor contributes
Primary tumors were measured using digital calipers on the days indicated. to angiogenesis and plasma extravasation in pathological conditions. Nat.
Tumor volumes were calculated according to the formula: width2  length Med. 7, 575–583.
0.52 as previously reported (Cao et al., 1999).
Clark, D.E., Smith, S.K., Licence, D., Evans, A.L., and Charnock-Jones,
D.S. (1998). Comparison of expression patterns for placenta growth factor,
Histology
vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human
At day 18 after implantation, mice were sacrificed, and tumors and livers placenta throughout gestation. J. Endocrinol. 159, 459–467.
were fixed in 3% PFA, dehydrated, and embedded in paraffin. Embedded
Clauss, M., Weich, H., Breier, G., Knies, U., Rockl, W., Waltenberger, J.,samples were sectioned and 4 m sections were immunostained using
and Risau, W. (1996). The vascular endothelial growth factor receptor Flt-1biotinylated monoclonal antibodies against CD31 (Pharmingen, San Diego,
mediates biological activities. Implications for a functional role of placentaCA). Peroxidase activity was developed with diaminobenzidine (DAB, Vector
growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 271,Laboratories Inc., Burlingame, CA) and sections were counterstained using
17629–17634.Mayer’s hematoxylin and Surgipath eosin. The tyramide signal amplification
(TSA) kit (NEN Life Science, Boston, MA) was used to enhance staining. DiSalvo, J., Bayne, M.L., Conn, G., Kwok, P.W., Trivedi, P.G., Soderman,
D.D., Palisi, T.M., Sullivan, K.A., and Thomas, K.A. (1995). Purification and
Statistical analysis characterization of a naturally occurring vascular endothelial growth factor-
placenta growth factor heterodimer. J. Biol. Chem. 270, 7717–7723.Statistical analysis was carried out using Student’s two-tailed t test in Micro-
soft Excel. P-values below 0.05 (*) and 0.001 (***) were deemed significant
Dvorak, H.F. (2000). VPF/VEGF and the angiogenic response. Semin. Perina-
and extremely significant, respectively. tol. 24, 75–78.
Eriksson, U., and Alitalo, K. (1999). Structure, expression and receptor-Acknowledgments
binding properties of novel vascular endothelial growth factors. Curr. Top.
Microbiol. Immunol. 237, 41–57.We thank Meit Bjo¨rndahl, Ebba Bra˚kenhielm, Johan Thyberg, and Niina
Veitonma¨ki for critical reading of the manuscript. This work was supported Ferrara, N., and Alitalo, K. (1999). Clinical applications of angiogenic growth
by the Human Frontier Science Program, the Swedish Cancer Foundation, factors and their inhibitors. Nat. Med. 5, 1359–1364.
the Karolinska Institute Foundation, the A˚ke Wibergs Foundation, David
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K.S.,Hagelen’s Foundation, and Hedberg’s Foundation and the Danish Health
Powell-Braxton, L., Hillan, K.J., and Moore, M.W. (1996). Heterozygous em-Science Reserarch Council. Y.C. is supported by the Karolinska Institute
bryonic lethality induced by targeted inactivation of the VEGF gene. Natureand the Swedish Research Council.
380, 439–442.
Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other
disease. Nat. Med. 1, 27–31.
Received: December 18, 2001
Fong, G.H., Rossant, J., Gertsenstein, M., and Breitman, M.L. (1995). Role
Revised: January 25, 2002 of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular
endothelium. Nature 376, 66–70.
References
Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms
of the angiogenic switch during tumorigenesis. Cell 86, 353–364.Benjamin, L.E., and Keshet, E. (1997). Conditional switching of vascular
endothelial growth factor (VEGF) expression in tumors: induction of endothe- Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., and Shibuya, M. (1998). Flt-1
lial cell shedding and regression of hemangioblastoma-like vessels by VEGF lacking the tyrosine kinase domain is sufficient for normal development and
withdrawal. Proc. Natl. Acad. Sci. USA 94, 8761–8766. angiogenesis in mice. Proc. Natl. Acad. Sci. USA 95, 9349–9354.
Cao, Y., Chen, H., Zhou, L., Chiang, M.K., Anand-Apte, B., Weatherbee, J.A., Hiratsuka, S., Maru, Y., Okada, A., Seiki, M., Noda, T., and Shibuya, M.
Wang, Y., Fang, F., Flanagan, J.G., and Tsang, M.L. (1996a). Heterodimers (2001). Involvement of Flt-1 tyrosine kinase (vascular endothelial growth
of placenta growth factor/vascular endothelial growth factor. Endothelial factor receptor-1) in pathological angiogenesis. Cancer Res. 61, 1207–1213.
activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J.
Huang, K., Andersson, C., Roomans, G.M., Ito, N., and Claesson-Welsh, L.Biol. Chem. 271, 3154–3162.
(2001). Signaling properties of VEGF receptor-1 and -2 homo- and hetero-
Cao, Y., Linden, P., Shima, D., Browne, F., and Folkman, J. (1996b). In vivo dimers. Int. J. Biochem. Cell Biol. 33, 315–324.
angiogenic activity and hypoxia induction of heterodimers of placenta growth
Kendall, R.L., and Thomas, K.A. (1993). Inhibition of vascular endothelial cellfactor/vascular endothelial growth factor. J. Clin. Invest. 98, 2507–2511.
growth factor activity by an endogenously encoded soluble receptor. Proc.
Cao, Y., Ji, W.R., Qi, P., and Rosin, A. (1997). Placenta growth factor: Natl. Acad. Sci. USA 90, 10705–10709.
identification and characterization of a novel isoform generated by RNA
Kuo, C.J., Farnebo, F., Yu, E.Y., Christofferson, R., Swearingen, R.A., Carter,alternative splicing. Biochem. Biophys. Res. Commun. 235, 493–498.
R., von Recum, H.A., Yuan, J., Kamihara, J., Flynn, E., et al. (2001). Compara-
tive evaluation of the antitumor activity of antiangiogenic proteins deliveredCao, Y., Linden, P., Farnebo, J., Cao, R., Eriksson, A., Kumar, V., Qi, J.H.,
Claesson-Welsh, L., and Alitalo, K. (1998). Vascular endothelial growth factor by gene transfer. Proc. Natl. Acad. Sci. USA 98, 4605–4610.
C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 95, 14389–14394.
Kurz, H., Wilting, J., Sandau, K., and Christ, B. (1998). Automated evaluation
of angiogenic effects mediated by VEGF and PlGF homo- and heterodimers.Cao, R., Wu, H.L., Veitonmaki, N., Linden, P., Farnebo, J., Shi, G.Y., and
Cao, Y. (1999). Suppression of angiogenesis and tumor growth by the inhibi- Microvasc. Res. 55, 92–102.
CANCER CELL : FEBRUARY 2002 107
A R T I C L E
Landgren, E., Schiller, P., Cao, Y., and Claesson-Welsh, L. (1998). Placenta of retrovirally transduced hematopoietic cells using CD24 as a marker of
gene transfer. Blood 84, 2868–2877.growth factor stimulates MAP kinase and mitogenicity but not phospholipase
C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 16,
Persico, M.G., Vincenti, V., and DiPalma, T. (1999). Structure, expression
359–367. and receptor-binding properties of placenta growth factor (PlGF). Curr. Top.
Microbiol. Immunol. 237, 31–40.Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P., and Persico, M.G.
(1991). Isolation of a human placenta cDNA coding for a protein related to Sawano, A., Takahashi, T., Yamaguchi, S., Aonuma, M., and Shibuya, M.
the vascular permeability factor. Proc. Natl. Acad. Sci. USA 88, 9267–9271. (1996). Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta
growth factor, which is related to vascular endothelial growth factor. CellMaglione, D., Guerriero, V., Viglietto, G., Ferraro, M.G., Aprelikova, O., Alitalo,
Growth Differ. 7, 213–221.K., Del Vecchio, S., Lei, K.J., Chou, J.Y., and Persico, M.G. (1993). Two
alternative mRNAs coding for the angiogenic factor, placenta growth factor Schratzberger, P., Schratzberger, G., Silver, M., Curry, C., Kearney, M.,
(PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8, Magner, M., Alroy, J., Adelman, L.S., Weinberg, D.H., Ropper, A.H., and
925–931. Isner, J.M. (2000). Favorable effect of VEGF gene transfer on ischemic periph-
eral neuropathy. Nat. Med. 6, 405–413.
Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand, S.J.,
Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., andRadziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos,
Dvorak, H.F. (1983). Tumor cells secrete a vascular permeability factor thatN., et al. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts
promotes accumulation of ascites fluid. Science 219, 983–985.in vivo angiogenesis. Science 277, 55–60.
Skobe, M., Hawighorst, T., Jackson, D.G., Prevo, R., Janes, L., Velasco, P.,Makinen, T., Jussila, L., Veikkola, T., Karpanen, T., Kettunen, M.I., Pulkkanen,
Riccardi, L., Alitalo, K., Claffey, K., and Detmar, M. (2001). Induction of tumorK.J., Kauppinen, R., Jackson, D.G., Kubo, H., Nishikawa, S., et al. (2001).
lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat.
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic Med. 7, 192–198.
mice expressing soluble VEGF receptor-3. Nat. Med. 7, 199–205.
Soker, S., Takashima, S., Miao, H.Q., Neufeld, G., and Klagsbrun, M. (1998).
Marconcini, L., Marchio, S., Morbidelli, L., Cartocci, E., Albini, A., Ziche, M., Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-
Bussolino, F., and Oliviero, S. (1999). c-fos-induced growth factor/vascular specific receptor for vascular endothelial growth factor. Cell 92, 735–745.
endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc.
Stacker, S.A., Caesar, C., Baldwin, M.E., Thornton, G.E., Williams, R.A.,Natl. Acad. Sci. USA 96, 9671–9676.
Prevo, R., Jackson, D.G., Nishikawa, S., Kubo, H., and Achen, M.G. (2001).
VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.Migdal, M., Huppertz, B., Tessler, S., Comforti, A., Shibuya, M., Reich, R.,
Nat. Med. 7, 186–191.Baumann, H., and Neufeld, G. (1998). Neuropilin-1 is a placenta growth
factor-2 receptor. J. Biol. Chem. 273, 22272–22278. Yancopoulos, G.D., Davis, S., Gale, N.W., Rudge, J.S., Wiegand, S.J., and
Holash, J. (2000). Vascular-specific growth factors and blood vessel forma-Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela,
tion. Nature 407, 242–248.O., Orpana, A., Pettersson, R.F., Alitalo, K., and Eriksson, U. (1996). Vascular
endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Zeng, H., Dvorak, H.F., and Mukhopadhyay, D. (2001). Vascular permeability
Natl. Acad. Sci. USA 93, 2576–2581. factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-
modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but
Park, J.E., Chen, H.H., Winer, J., Houck, K.A., and Ferrara, N. (1994). Placenta not migration, through phosphatidylinositol 3-kinase-dependent pathways.
growth factor. Potentiation of vascular endothelial growth factor bioactivity, J. Biol. Chem. 276, 26969–26979.
in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.
Ziche, M., Maglione, D., Ribatti, D., Morbidelli, L., Lago, C.T., Battisti, M.,J. Biol. Chem. 269, 25646–25654.
Paoletti, I., Barra, A., Tucci, M., Parise, G., et al. (1997). Placenta growth
factor-1 is chemotactic, mitogenic, and angiogenic. Lab. Invest. 76, 517–531.Pawliuk, R., Kay, R., Lansdorp, P., and Humphries, R.K. (1994). Selection
108 CANCER CELL : FEBRUARY 2002
